Gelonghui, Feb. 23 | Digi Pharmaceutical (688192.SH) announced its 2023 annual performance report. During the reporting period, the company achieved total operating income of 91.2886 million yuan; net profit attributable to owners of the parent company - 1,123 million yuan; net profit attributable to owners of the parent company after deducting non-recurring profit and loss - 1,177 million yuan; basic earnings per share - 2.75 yuan
迪哲医药(688192.SH)业绩快报：2023年度净亏损11.23亿元
Digel Pharmaceutical (688192.SH) Performance Report: Net loss of 1,123 billion yuan in 2023
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.